Aurisco PharmaceuticalLtd Croissance future
Future contrôle des critères 5/6
Aurisco PharmaceuticalLtd is forecast to grow earnings and revenue by 27.4% and 23% per annum respectively. EPS is expected to grow by 27.4% per annum. Return on equity is forecast to be 19.6% in 3 years.
Informations clés
27.4%
Taux de croissance des bénéfices
27.4%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 19.3% |
Taux de croissance des recettes | 23.0% |
Rendement futur des capitaux propres | 19.6% |
Couverture par les analystes | Low |
Dernière mise à jour | 07 Oct 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
Is Aurisco PharmaceuticalLtd (SHSE:605116) A Risky Investment?
Sep 19Is Now The Time To Put Aurisco PharmaceuticalLtd (SHSE:605116) On Your Watchlist?
Aug 14Investors Interested In Aurisco Pharmaceutical Co.,Ltd.'s (SHSE:605116) Earnings
Jun 28Aurisco PharmaceuticalLtd (SHSE:605116) Has A Pretty Healthy Balance Sheet
Jun 07Investors Shouldn't Be Too Comfortable With Aurisco PharmaceuticalLtd's (SHSE:605116) Earnings
May 12Here's Why We Think Aurisco PharmaceuticalLtd (SHSE:605116) Might Deserve Your Attention Today
Apr 22Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 2,436 | 638 | N/A | 590 | 3 |
12/31/2025 | 2,033 | 523 | N/A | 472 | 3 |
12/31/2024 | 1,627 | 395 | N/A | 360 | 3 |
9/30/2024 | 1,428 | 341 | -151 | 398 | N/A |
6/30/2024 | 1,441 | 382 | -46 | 405 | N/A |
3/31/2024 | 1,296 | 326 | -9 | 395 | N/A |
12/31/2023 | 1,263 | 289 | 80 | 386 | N/A |
9/30/2023 | 1,162 | 257 | 80 | 367 | N/A |
6/30/2023 | 1,052 | 190 | 9 | 242 | N/A |
3/31/2023 | 1,091 | 216 | 14 | 221 | N/A |
12/31/2022 | 1,008 | 211 | -50 | 166 | N/A |
9/30/2022 | 983 | 222 | -122 | 130 | N/A |
6/30/2022 | 911 | 202 | -82 | 185 | N/A |
3/31/2022 | 836 | 177 | -52 | 203 | N/A |
12/31/2021 | 803 | 169 | -49 | 202 | N/A |
9/30/2021 | 767 | 151 | -15 | 171 | N/A |
6/30/2021 | 741 | 137 | -10 | 172 | N/A |
3/31/2021 | 727 | 140 | 34 | 220 | N/A |
12/31/2020 | 721 | 157 | 56 | 214 | N/A |
9/30/2020 | 688 | 206 | 143 | 255 | N/A |
12/31/2019 | 582 | 186 | 107 | 180 | N/A |
12/31/2018 | 575 | 137 | 16 | 110 | N/A |
12/31/2017 | 544 | 45 | N/A | 118 | N/A |
12/31/2016 | 590 | 87 | N/A | 188 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 605116's forecast earnings growth (27.4% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 605116's earnings (27.4% per year) are forecast to grow faster than the CN market (25.8% per year).
Croissance élevée des bénéfices: 605116's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 605116's revenue (23% per year) is forecast to grow faster than the CN market (14% per year).
Croissance élevée des revenus: 605116's revenue (23% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 605116's Return on Equity is forecast to be low in 3 years time (19.6%).